Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 20, 2018 Category: Cancer & Oncology Source Type: research

Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 17, 2018 Category: Cancer & Oncology Source Type: research

Response to the Comments on Cicalese et al.: “An Ecological Study of the Association between Air Pollution and Hepatocellular Carcinoma Incidence in Texas”
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 12, 2018 Category: Cancer & Oncology Source Type: research

Vinyl Institute Comments on Cicalese et al.: “An Ecological Study of the Association between Air Pollution and Hepatocellular Carcinoma Incidence in Texas”
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 11, 2018 Category: Cancer & Oncology Source Type: research

European Council of Vinyl Manufacturers Comments on Cicalese et al.: “An Ecological Study of the Association between Air Pollution and Hepatocellular Carcinoma Incidence in Texas”
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 11, 2018 Category: Cancer & Oncology Source Type: research

No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma
Conclusions: We identified no muscle depletion with H-VFA as a novel biomarker for advanced HCC patients treated with sorafenib.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 6, 2018 Category: Cancer & Oncology Source Type: research

Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment
Transarterial chemoembolization (TACE) is the first-line treatment in patients with unresectable hepatocellular carcinoma (HCC). In recent years, there has been increasing clinical evidence that drug-eluting beads provide a combined ischemic and cytotoxic effect that may be superior to conventional TACE, with low systemic toxicity. The therapeutic value of TACE performed using the embolic microsphere DC Bead loaded with doxorubicin (drug-eluting bead doxorubicin [DEBDOX]) has been shown by several randomized controlled trials. Since Lencioni et al. [Cardiovasc Intervent Radiol 2012; 35: 980 –985] published the first wide...
Source: Liver Cancer - March 29, 2018 Category: Cancer & Oncology Source Type: research

A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
Conclusions: Nintedanib showed numerically similar efficacy to sorafenib for CIR TTP and OS in Asian patients with advanced HCC and adequate liver function. AEs were generally manageable.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 15, 2018 Category: Cancer & Oncology Source Type: research

The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade
Conclusion: Patients in the SLHCC group had an overall survival rate intermediate to those of the BCLC-A and BCLC-B groups. It is suggested that the SLHCC group could be classified as occupying a different stage from the BCLC stages A and B. The ALBI grade could help to stratify SLHCC into a different prognostic group. However, the results need to be validated externally in other regions of the world.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 14, 2018 Category: Cancer & Oncology Source Type: research

Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study
Conclusions: The local control rates after PRT were sufficiently high compared to TACE or sorafenib. Thus, PRT should be adopted for patients with difficult-to-treat HCC in the early and intermediate stages.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 14, 2018 Category: Cancer & Oncology Source Type: research

Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status
Conclusion: The prognostic factors varied according to the duration after hepatic resection for HCV-related HCC. Tumor-related factors were unfavorable prognostic factors in the early postoperative period, whereas SVR and good liver function were favorable prognostic factors at 10 and 15 years postoperatively. Achievement of SVR with IFN therapy is essential for long-term ( ≥15 years) survival after hepatic resection for HCV-related HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 14, 2018 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2018;7:120 –120 (Source: Liver Cancer)
Source: Liver Cancer - March 12, 2018 Category: Cancer & Oncology Source Type: research

The APPLE Association President's Message
Liver Cancer 2018;7:121 –121 (Source: Liver Cancer)
Source: Liver Cancer - March 12, 2018 Category: Cancer & Oncology Source Type: research

Immune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor Recurrence
Conclusions: Immune gene expression profiles predictive of TTR could be identified both in HCC and in adjacent cirrhotic tissues. Longer TTR was associated with overexpression in T tissue and downregulation in NT tissue of the immune response and of inflammation-related genes.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 7, 2018 Category: Cancer & Oncology Source Type: research

Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma
In conclusion, outcomes after LT for intermediate-stage HCC are more favorable if patients meet our extended criteria.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 1, 2018 Category: Cancer & Oncology Source Type: research